FDA Changes Regulations on ZYN Marketing
Recently, there’s been a noticeable trend of individuals opting for smokeless alternatives over traditional cigarettes, presumably in search of healthier options. The Food and Drug Administration has now endorsed this shift by updating its regulations concerning one popular brand.
On Tuesday, the FDA issued new guidelines enabling ZYN, produced by Sweden’s Match USA Inc., to promote its products in a way that implies they offer a healthier alternative to cigarettes. The updated labeling allows the claim: “Using ZYN instead of cigarettes reduces the risk of oral cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
Philip Morris U.S. CEO Stacey Kennedy remarked that the FDA’s decision is significant for over 45 million nicotine consumers in the U.S., granting them access to scientific information that supports the idea that switching from cigarettes to ZYN may lower the risk of smoking-related illnesses.
The new rules apply to ten flavors of the original product line, with two concentration options: 3 milligrams and 6 milligrams. These flavors include Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen. Interestingly, this approved messaging does not extend to ZYN’s newer flavors: Peach, Black Cherry, and Dragonberry.
Brett Koplau, acting director of the FDA’s Center for Tobacco Products, explained that this review aims to provide adult users with clear, science-based information regarding the relative harms of tobacco products, enabling informed choices. The decision allows for modified risk claims that suggest these products carry lower risks.
However, it’s important to highlight that this regulatory update serves as a marketing authorization, not an “FDA approval.” The agency maintains that “no tobacco product is safe” and focuses on “relative risk” instead.
According to the FDA’s guidelines, any application for marketing authorization must demonstrate that the product significantly diminishes the risk of harm and related diseases for individual users, while also offering public health benefits.
